CALR and cancer: Calreticulin is the dominant signal in multiple human cancers counteracted by CD47 [46]; moreover, in cancer cells that express calreticulin on their cell surface, increased CD47 has been shown to protect them from calreticulin-mediated phagocytosis, and when CD47 is blocked, cancer cells are killed by macrophages [20].